Collegium Pharmaceutical Inc (COLL) Expected to Announce Earnings of -$0.19 Per Share

Equities analysts expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to announce ($0.19) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Collegium Pharmaceutical’s earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.24). Collegium Pharmaceutical reported earnings per share of ($0.15) in the same quarter last year, which suggests a negative year-over-year growth rate of 26.7%. The company is scheduled to report its next earnings results on Wednesday, August 14th.

According to Zacks, analysts expect that Collegium Pharmaceutical will report full year earnings of ($0.40) per share for the current year, with EPS estimates ranging from ($0.81) to $0.05. For the next year, analysts forecast that the business will post earnings of $0.32 per share, with EPS estimates ranging from ($0.02) to $0.54. Zacks’ EPS averages are an average based on a survey of analysts that follow Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. Collegium Pharmaceutical had a negative net margin of 10.36% and a negative return on equity of 30.87%. The firm had revenue of $74.52 million for the quarter, compared to analyst estimates of $70.10 million.

Several research firms recently commented on COLL. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a report on Monday, March 25th. ValuEngine raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd. Cantor Fitzgerald set a $35.00 price objective on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Friday, April 26th. HC Wainwright initiated coverage on shares of Collegium Pharmaceutical in a research report on Friday, May 3rd. They issued a “buy” rating and a $23.00 price objective for the company. Finally, BidaskClub downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, May 20th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $27.29.

In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $17.17, for a total value of $429,250.00. Following the completion of the sale, the director now owns 227,362 shares of the company’s stock, valued at $3,903,805.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joseph Ciaffoni sold 5,851 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $11.52, for a total transaction of $67,403.52. Following the sale, the chief executive officer now directly owns 190,755 shares of the company’s stock, valued at approximately $2,197,497.60. The disclosure for this sale can be found here. Insiders sold 88,287 shares of company stock valued at $1,281,087 in the last ninety days. 8.08% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Macquarie Group Ltd. lifted its stake in Collegium Pharmaceutical by 8.7% during the fourth quarter. Macquarie Group Ltd. now owns 2,759,007 shares of the specialty pharmaceutical company’s stock worth $47,372,000 after purchasing an additional 221,779 shares during the last quarter. BlackRock Inc. lifted its stake in Collegium Pharmaceutical by 8.7% during the fourth quarter. BlackRock Inc. now owns 2,619,718 shares of the specialty pharmaceutical company’s stock worth $44,980,000 after purchasing an additional 210,145 shares during the last quarter. Vanguard Group Inc. lifted its stake in Collegium Pharmaceutical by 9.0% during the third quarter. Vanguard Group Inc. now owns 1,375,709 shares of the specialty pharmaceutical company’s stock worth $20,278,000 after purchasing an additional 113,038 shares during the last quarter. Millennium Management LLC lifted its stake in Collegium Pharmaceutical by 863.4% during the fourth quarter. Millennium Management LLC now owns 1,305,001 shares of the specialty pharmaceutical company’s stock worth $22,407,000 after purchasing an additional 1,169,537 shares during the last quarter. Finally, Rice Hall James & Associates LLC lifted its stake in Collegium Pharmaceutical by 27.8% during the first quarter. Rice Hall James & Associates LLC now owns 1,191,141 shares of the specialty pharmaceutical company’s stock worth $18,034,000 after purchasing an additional 259,015 shares during the last quarter. 94.15% of the stock is owned by institutional investors and hedge funds.

NASDAQ COLL traded up $0.03 during mid-day trading on Tuesday, hitting $10.65. The company’s stock had a trading volume of 5,486 shares, compared to its average volume of 339,699. Collegium Pharmaceutical has a 52-week low of $10.55 and a 52-week high of $28.91. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.19 and a current ratio of 1.24. The firm has a market capitalization of $354.60 million, a price-to-earnings ratio of -8.95 and a beta of 0.47.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Read More: What is the Ex-Dividend Date in Investing?

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.